Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.83 |
| ▸ | MEN1 | O00255 | 2/20 | 0.83 |
| ▸ | GAA | P10253 | 2/20 | 0.69 |
| ▸ | POLB | P06746 | 2/20 | 0.69 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.66 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.66 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | EBP | Q15125 | 2/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.61 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31178415 | 1.00 | KMT2A (0.83) | KMT2AMEN1GAAPOLBTLR9 | |
| SCHEMBL31178346 | 0.96 | KMT2A (0.77) | KMT2AMEN1GAAPOLBTLR9 | |
| SCHEMBL25242104 | 0.96 | KMT2A (0.77) | KMT2AMEN1GAAPOLBTLR9 | |
| SCHEMBL31178374 | 0.93 | KMT2A (0.96) | KMT2AMEN1GAAPOLBTLR9 | |
| SCHEMBL25286763 | 0.93 | KMT2A (0.96) | KMT2AMEN1GAAPOLBTLR9 | |
| SCHEMBL25237358 | 0.92 | KMT2A (0.90) | KMT2AMEN1GAAPOLBTLR9 | |
| SCHEMBL31178332 | 0.92 | KMT2A (0.90) | KMT2AMEN1GAAPOLBTLR9 | |
| SCHEMBL9513195 | 0.89 | DRD2 (0.69) | KMT2AMEN1GAAPOLBALDH1A1 | |
| SCHEMBL9514285 | 0.88 | KMT2A (0.67) | KMT2AMEN1GAAPOLBALDH1A1 | |
| SCHEMBL9513235 | 0.88 | KMT2A (0.67) | KMT2AMEN1GAAPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0250361-B1 | Disubstituted piperazines | CIBA GEIGY AG (CH) | 1993-12-08 | — | — | EP | claimed |
| US-20250066320-A1 | Active Ingredients with Sialagogue and Tingling/Fizzy Effect, and Preparations Containing Same | SYMRISE AG (DE) | 2025-02-27 | — | — | US | disclosed |
| EP-4452941-A1 | ACTIVE INGREDIENTS WITH SIALAGOGUE AND TINGLING/FIZZY EFFECT, AND PREPARATIONS CONTAINING SAME | Symrise AG (DE) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023117119-A1 | ACTIVE INGREDIENTS WITH SIALAGOGUE AND TINGLING/FIZZY EFFECT, AND PREPARATIONS CONTAINING SAME | SYMRISE AG (DE) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023117119-A1 | ACTIVE INGREDIENTS WITH SIALAGOGUE AND TINGLING/FIZZY EFFECT, AND PREPARATIONS CONTAINING SAME | SYMRISE AG (DE) | 2023-06-29 | — | — | WO | disclosed |
| US-4804661-A | ANALGESICS | CIBA-GEIGY CORPORATION (US) | 1989-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066320-A1 | Active Ingredients with Sialagogue and Tingling/Fizzy Effect, and Preparations Containing Same | TAS2R5, TAS2R7, TAS2R8 | KMT2A 2748/4885MEN1 714/4885GAA 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.